8,872 results match your criteria Breast Cancer Res. Treat.[Journal]


Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.

Breast Cancer Res Treat 2019 Apr 17. Epub 2019 Apr 17.

Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.

Purpose: In breast cancer, hormone receptor (HR) status is generally a qualitative measure; positive or negative. Quantitatively measured oestrogen and progesterone receptors (ER and PR) are frequently proposed prognostic and predictive markers, some guidelines even provide different treatment options for patients with strong versus weak expression.

Aim: To evaluate quantitative HR load assessed by immunohistochemistry as a prognostic and predictive measure in stage 1-3 breast cancer. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05233-9
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05233-9DOI Listing
April 2019
2 Reads

Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer.

Breast Cancer Res Treat 2019 Apr 17. Epub 2019 Apr 17.

Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.

Purpose: Treatments for breast cancer can lead to chronic musculoskeletal problems. This study aimed to systematically review the evidence surrounding the cost-effectiveness of exercise and physiotherapy interventions aimed at reducing the risk of physical symptoms and functional limitations due to breast cancer treatment.

Methods: A systematic review of the cost-effectiveness of exercise and physiotherapy interventions during and following treatment for breast cancer was undertaken according to PRISMA guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05235-7DOI Listing
April 2019
1 Read

Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients.

Breast Cancer Res Treat 2019 Apr 17. Epub 2019 Apr 17.

Breast Epidemiology Unit, National Institute of Cancer (INCan), Mexico City, Mexico.

Purpose: The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC).

Methods: We retrospectively analyzed a database of 4533 non-metastatic BC patients treated for BC at the National Cancer Institute in Mexico (INCan) between 2006 and 2016. We compared clinical characteristics, treatment and survival between women with invasive ductal and invasive lobular BC. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05234-8
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05234-8DOI Listing
April 2019
2 Reads

Propagation of functional estrogen receptor positive normal human breast cells in 3D cultures.

Breast Cancer Res Treat 2019 Apr 16. Epub 2019 Apr 16.

Environmental Genomics & Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.

Purpose: Understanding how differentiation, microenvironment, and hormonal milieu influence human breast cell susceptibility to malignant transformation will require the use of physiologically relevant in vitro systems. We sought to develop a 3D culture model that enables the propagation of normal estrogen receptor alpha (ER) + cells.

Methods: We tested soluble factors and protocols for the ability to maintain progenitor and ER + cells in cultures established from primary cells. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05229-5
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05229-5DOI Listing
April 2019
1 Read

Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.

Breast Cancer Res Treat 2019 Apr 13. Epub 2019 Apr 13.

Center for Cancer and Aging, City of Hope National Medical Center, Duarte, CA, USA.

Purpose: Older cancer patients are at increased risk of cancer-related cognitive impairment. The purpose of this study was to assess the alterations in intrinsic brain activity associated with adjuvant chemotherapy in older women with breast cancer.

Methods: Chemotherapy treatment (CT) group included sixteen women aged ≥ 60 years (range 60-82 years) with stage I-III breast cancers, who underwent both resting-state functional magnetic resonance imaging (rs-fMRI) and neuropsychological testing with NIH Toolbox for Cognition before adjuvant chemotherapy, at time point 1 (TP1), and again within 1 month after completing chemotherapy, at time point 2 (TP2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05230-yDOI Listing

Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.

Breast Cancer Res Treat 2019 Apr 15. Epub 2019 Apr 15.

Department of Oncology, The Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, Shanxi, China.

Purpose: Targeting DNA repair mechanisms to induce apoptosis may be a promising strategy for breast cancer treatment. Olaparib is proved to have anticancer effect by inhibiting DNA repairing protein poly (ADP-ribose) polymerase (PARP). However, the cytotoxicity of olaparib is very limited to homologous recombination-proficient cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05189-wDOI Listing

miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.

Breast Cancer Res Treat 2019 Apr 15. Epub 2019 Apr 15.

Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea.

Purpose: Ductal carcinoma in situ (DCIS) is well-known precursor of invasive ductal carcinoma (IDC). Parts of patients show recurrence as DCIS or IDC after local treatment, but there are no established markers predicting relapse. We analyzed changes in miRNA and oncogene expression during DCIS progression/evolution to identify potential markers predicting recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05192-1DOI Listing

Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Breast Cancer Res Treat 2019 Apr 15. Epub 2019 Apr 15.

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030-4009, USA.

Unfortunately in the original publication of the article, the author's funding support has been mentioned incorrectly. The correct funding statement should read as "This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson's Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC."The first affiliations was incorrect in the original article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05218-8DOI Listing

Pathologic discordance to clinical management decisions suggests overtreatment in pediatric benign breast disease.

Breast Cancer Res Treat 2019 Apr 13. Epub 2019 Apr 13.

Department of Surgery, Massachusetts General Hospital, 55 Fruit St., GRB-425, Boston, MA, 02114, USA.

Purpose: Breast masses in pediatric patients are often managed similarly to adult breast masses despite significant differences in pathology and natural history. Emerging evidence suggests that clinical observation is safe. The purpose of this study was to quantify the clinical appropriateness of the management of benign breast disease in pediatric patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05224-wDOI Listing

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Breast Cancer Res Treat 2019 Apr 13. Epub 2019 Apr 13.

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.

Purpose: Brain metastases from breast cancer are frequently managed with brain-directed radiation but the impact of subtype on intracranial recurrence patterns after radiation has not been well-described. We investigated intracranial recurrence patterns of brain metastases from breast cancer after brain-directed radiation to facilitate subtype-specific management paradigms.

Methods: We retrospectively analyzed 349 patients with newly diagnosed brain metastases from breast cancer treated with brain-directed radiation at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2000 and 2015. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05236-6
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05236-6DOI Listing
April 2019
2 Reads

Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.

Breast Cancer Res Treat 2019 Apr 12. Epub 2019 Apr 12.

Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Purpose: Uptake of biosimilars depends on clinicians and patients having confidence in the evidential basis of marketing approval. The aim of this systematic review was to assess the evidential role of randomised clinical endpoint studies in the marketing approval of trastuzumab biosimilars.

Methods: We searched PubMed for any published reports of randomised studies associated with the five trastuzumab biosimilars approved by the EMA, as on 31 January 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05227-7DOI Listing

Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.

Breast Cancer Res Treat 2019 Apr 12. Epub 2019 Apr 12.

Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, 52621, Tel-Hashomer, Israel.

Background: Studies assessing the contribution of non-BRCA1/2 gene mutations to inherited breast cancer (BC) predisposition consistently reported low (up to 4%) yield. The current study aimed at assessing the spectrum of non-BRCA mutations in unselected Israeli BC cases and the utility of BRCAPRO and Penn II models, as tools for prediction of detecting non-BRCA1/2 mutations in Israeli BC patients who tested negative for the predominant Jewish BRCA1/2 mutations.

Methods: All consecutive Jewish Israeli BC patients at the Sheba Medical center who tested negative for the predominant BRCA1/2 mutations and elected to perform multigene panel testing were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05228-6DOI Listing

The association between mammographic density and breast cancer risk in Western Australian Aboriginal women.

Breast Cancer Res Treat 2019 Apr 12. Epub 2019 Apr 12.

Centre for Genetic Origins of Health and Disease, Curtin University and The University of Western Australia, 35 Stirling Highway, M409, Perth, WA, 6009, Australia.

Purpose: Mammographic density is an established breast cancer risk factor within many ethnically different populations. The distribution of mammographic density has been shown to be significantly lower in Western Australian Aboriginal women compared to age- and screening location-matched non-Aboriginal women. Whether mammographic density is a predictor of breast cancer risk in Aboriginal women is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05225-9DOI Listing
April 2019
2 Reads

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).

Breast Cancer Res Treat 2019 Apr 11. Epub 2019 Apr 11.

Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Purpose: Lapatinib (L) is approved in combination with capecitabine or letrozole for patients with trastuzumab-resistant HER2-positive metastatic breast cancer (MBC). However, there is no efficacy data of L in patients who received prior pertuzumab (P) and ado-trastuzumab emtansine (T-DM1), now included as standard first- and second-line therapies, respectively. The goal of this study was to assess the efficacy of L in a contemporary patient population that received prior P and/or T-DM1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05081-zDOI Listing
April 2019
1 Read

Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.

Breast Cancer Res Treat 2019 Apr 11. Epub 2019 Apr 11.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 201 N. Broadway, Rm 10262, Baltimore, MD, 21231, USA.

Purpose: Determining the need for adjuvant chemotherapy in estrogen receptor (ER)+ disease can be influenced by pathological characteristics and gene expression assays [i.e., Oncotype Dx recurrence scores (RSs)]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05088-6DOI Listing
April 2019
1 Read

Improving surgical efficiency of immediate implant-based breast reconstruction following mastectomy.

Breast Cancer Res Treat 2019 Apr 11. Epub 2019 Apr 11.

Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.

Purpose: Traditionally, during a mastectomy with implant-based reconstruction, the surgical oncologist completes their operative procedure prior to the reconstructive surgeon entering the room. In this scenario, two separate instruments kits and tables are utilized. In our institution, we created a combined instrument kit for use by both surgical teams. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05175-2DOI Listing
April 2019
1 Read

Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.

Breast Cancer Res Treat 2019 Apr 10. Epub 2019 Apr 10.

Department of Surgical Oncology, Radboud University Medical Center Nijmegen, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.

Purpose: To analyze the influence of hormone receptors (HR) and Human Epidermal growth factor Receptor-2 (HER2)-based molecular subtypes in stage III inflammatory breast cancer (IBC) on tumor characteristics, treatment, pathologic response to neoadjuvant chemotherapy (NACT), and overall survival (OS).

Methods: Patients with stage III IBC, diagnosed in the Netherlands between 2006 and 2015, were classified into four breast cancer subtypes: HR+/HER2- , HR+/HER2+ , HR-/HER2+ , and HR-/HER2- . Patient-, tumor- and treatment-related characteristics were compared. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05219-7
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05219-7DOI Listing
April 2019
4 Reads

Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?

Breast Cancer Res Treat 2019 Apr 10. Epub 2019 Apr 10.

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

Purpose: Since 2012, about 80 specialty societies have released Choosing Wisely (CW) recommendations aimed at reducing the use of low-value, unproven, or ineffective medical services. The extent to which these recommendations have influenced the behavior of physicians and patients remains largely unknown.

Methods: Using MarketScan Commercial Claims and Medicare Supplemental and Coordination of Benefits databases, we identified annual cohorts of women with incident, early-stage breast cancer and estimated the prevalence of four initial treatment and six surveillance metrics deemed as low-value breast cancer care by CW. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05213-zDOI Listing

Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis.

Breast Cancer Res Treat 2019 Apr 6. Epub 2019 Apr 6.

Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.

Purpose: We conducted a meta-analysis evaluating the effects of different exercise interventions on self-reported and objective sleep measurements during or after breast cancer treatment.

Methods: Three databases were systematically searched for randomized controlled trials with any type of exercise intervention in women with breast cancer. Outcomes were self-reported or objective sleep measurements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05217-9DOI Listing
April 2019
2 Reads

Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.

Breast Cancer Res Treat 2019 Apr 6. Epub 2019 Apr 6.

Department of Biostatistics and Epidemiology, University of Massachusetts, 715 North Pleasant Street, Amherst, MA, 01003, USA.

Purpose: We examined the association of plasma B-vitamins and metabolites, and related genetic variants, with risk of breast cancer among predominantly premenopausal women.

Methods: We conducted a nested case-control study within the Nurses' Health Study II. From blood samples collected in 1996-1999 and follow-up through 2007, plasma measures were available for 610 cases and 1207 controls. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05223-x
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05223-xDOI Listing
April 2019
5 Reads

Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval.

Breast Cancer Res Treat 2019 Apr 6. Epub 2019 Apr 6.

Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.

Purpose: In patients with ipsilateral breast tumor recurrence (IBTR), the detection of distant disease determines whether the intention of the treatment is curative or palliative. Therefore, adequate preoperative staging is imperative for optimal treatment planning. The aim of this study is to evaluate the impact of conventional imaging techniques, including chest X-ray and/or CT thorax-(abdomen), liver ultrasonography(US), and skeletal scintigraphy, on the distant recurrence-free interval (DRFI) in patients with IBTR, and to compare conventional imaging with F-FDG PET-CT or no imaging at all. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05205-zDOI Listing
April 2019
1 Read

Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm.

Breast Cancer Res Treat 2019 Apr 5. Epub 2019 Apr 5.

Department of Ultrasound, Chinese People's Liberation Army General Hospital, The Southern Building, 28 Fuxing Road, Beijing, 100853, China.

Purpose: To develop and evaluate the accuracy of a three-dimensional (3D) US method for assessing unilateral breast reconstruction and discuss the feasibility of breast ultrasound 3D reconstruction of the unilateral breast compared with 3D MRI.

Methods: Sixty-four breast lesions were collected for surgical resection. (1) MRI and US imaging were used to reconstruct the 3D models of the breast neoplasm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05202-2DOI Listing
April 2019
1 Read
3.940 Impact Factor

Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues.

Breast Cancer Res Treat 2019 Apr 4. Epub 2019 Apr 4.

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Purpose: The use of formalin-fixed paraffin-embedded (FFPE) tumor tissues in flow cytometry (FCM)-based determination of tumor cell DNA content is more complicated than the use of fresh-frozen tissues. This study aimed to accurately measure tumor cell DNA content from FFPE tissues by separating tumor cells from stromal cells through FCM and investigating its prognostic impact.

Methods: We separately measured the DNA contents of tumor cells and stromal cells by gating with pan-cytokeratin and vimentin (FCM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05222-yDOI Listing

GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event.

Breast Cancer Res Treat 2019 Apr 4. Epub 2019 Apr 4.

Department of Radiation Oncology, Antoine Lacassagne Cancer Center & University of Cote d'Azur, 33 Avenue Valombrose, 06107, Nice Cedex, France.

Aim: Second ipsilateral breast tumor event (2ndIBTE) occurring after primary radio-surgical treatment can be treated by either salvage mastectomy or 2nd conservative treatment (2ndCT) including an accelerated partial breast re-irradiation (APBrI). We analyzed the impact of the GEC-ESTRO APBI classification (GAC) on the oncological outcome after APBrI.

Materials And Methods: Between 2000 and 2016, 159 patients (pts) underwent a 2ndCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05221-zDOI Listing
April 2019
1 Read

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.

Breast Cancer Res Treat 2019 Apr 2. Epub 2019 Apr 2.

Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Charterhouse Square, Barts and The London, Queen Mary University of London, London, UK.

Purpose: To improve breast cancer risk stratification to enable more targeted early detection/prevention strategies that will better balance risks and benefits of population screening programmes.

Methods: 9362 of 57,902 women in the Predicting-Risk-Of-Cancer-At-Screening (PROCAS) study who were unaffected by breast cancer at study entry and provided DNA for a polygenic risk score (PRS). The PRS was analysed alongside mammographic density (density-residual-DR) and standard risk factors (Tyrer-Cuzick-model) to assess future risk of breast cancer based on tumour stage receptor expression and pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05210-2DOI Listing
April 2019
2 Reads

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Breast Cancer Res Treat 2019 Apr 2. Epub 2019 Apr 2.

Division of Cancer and Stem Cells, Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham, UK.

Purpose: Androgen receptor (AR) and AR signaling pathways are thought to play a role in breast cancer (BC) and are potentially related to treatment responses and outcomes. Ankyrin 3 (ANK3) is associated with AR stability in cancer cells. In the present study, we investigated the clinicopathological utility of ANK3 expression with emphasis on AR and its associated signalling pathway at transcriptomic and proteomic phases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05216-wDOI Listing
April 2019
5 Reads
3.940 Impact Factor

Applying a value-based care framework to post-mastectomy reconstruction.

Breast Cancer Res Treat 2019 Apr 1. Epub 2019 Apr 1.

Department of Plastic & Reconstructive Surgery, MD Anderson Cancer Center, Houston, TX, 77030, USA.

Purpose: Reconstructive breast surgeons, like all procedural care providers, face a transition from volume reimbursement (i.e., per unit of service) to value-based care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05212-0DOI Listing

Body mass index impacts infection rates in immediate autogenous breast reconstruction.

Breast Cancer Res Treat 2019 Apr 1. Epub 2019 Apr 1.

Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Toronto, 149 College Street, 5th Floor, Suite 508, Toronto, ON, M5T 1P5, Canada.

Purpose: Risk of postoperative infection following breast cancer reconstruction warrants consideration of both classic and procedure-specific risk factors. We performed a retrospective chart review of patients with breast cancer over a 10-year period that underwent reconstructive surgery to identify factors that increase risk of postoperative infection.

Methods: Rates of postoperative infection were assessed in primary (immediate or delayed, alloplastic or autogenous) and secondary reconstructive procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05215-xDOI Listing

4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.

Breast Cancer Res Treat 2019 Apr 1. Epub 2019 Apr 1.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.

Purpose: In early stage, ERα-positive breast cancer, concurrent use of endocrine therapy and chemotherapy has not been shown to be superior to sequential use. We hypothesized that genetic biomarkers can aid in selecting patients who would benefit from chemo-endocrine therapy. Our previous studies revealed that ZNF423 is a transcription factor for BRCA1 and an intronic single nucleotide polymorphism (SNP) in ZNF423, rs9940645, determines tamoxifen response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05194-zDOI Listing
April 2019
2 Reads

Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.

Breast Cancer Res Treat 2019 Apr 1. Epub 2019 Apr 1.

Department of Breast Disease, Peking Union Medical College Hospital, Peking Union Medical College, 1 Shuaifuyuan, Wangfujing, Beijing, 100730, China.

Purpose: To evaluate and compare the efficacy and safety of the taxane plus anthracycline (TA) regimen vs. the taxane plus anthracycline plus cyclophosphamide (TAC) regimen as adjuvant chemotherapy in Chinese patients with node-positive breast cancer (BCa).

Methods: Patients with BCa (n = 640) were recruited between January 2010 and June 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05207-xDOI Listing

Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.

Breast Cancer Res Treat 2019 Mar 30. Epub 2019 Mar 30.

Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski St, Petach Tikva, Israel.

Purpose: There is uncertainty about outcomes differences between partial breast irradiation (PBI) and whole breast irradiation (WBI) for early-stage breast cancer.

Methods: Prospective randomized trials comparing adjuvant PBI to WBI in early-stage invasive breast cancer were identified using PubMed. Odds ratios (OR), 95% confidence intervals and absolute risks were computed for pre-specified efficacy and toxicity outcomes including cosmesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05209-9DOI Listing

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.

Breast Cancer Res Treat 2019 Mar 27. Epub 2019 Mar 27.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

Purpose: This study evaluated development of edema in patients receiving PI3K/mTOR/CDK4/6 targeted therapy for metastatic breast cancer (MBC).

Methods: We reviewed medical records of 160 patients receiving targeted therapy with PI3K/mTOR/CDK4/6 inhibitors to treat MBC (n = 160; 185 treatment occurrences). Clinicopathologic data, treatment details, and edema incidence were recorded. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05206-y
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05206-yDOI Listing
March 2019
7 Reads

Two-year follow-up of the OptiTrain randomised controlled exercise trial.

Breast Cancer Res Treat 2019 Mar 26. Epub 2019 Mar 26.

Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 23, 14183, Stockholm, Sweden.

Purpose: The aim of this study was to determine if there were any differences in health-related outcomes and physical activity (PA) between the two OptiTrain exercise groups and usual care (UC), 2 years post-baseline.

Methods: The OptiTrain study was a three-arm randomised controlled trial comparing 16 weeks of concurrent aerobic high-intensity interval training (HIIT) and progressive resistance exercise (RT-HIIT) or concurrent HIIT and continuous moderate-intensity aerobic exercise (AT-HIIT) to UC in 206 patients with breast cancer undergoing chemotherapy. Eligible participants were approached 2 years following baseline to assess cancer-related fatigue, quality of life, symptoms, muscle strength, cardiorespiratory fitness, body mass, PA, sedentary behaviour, and sick leave. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05204-0DOI Listing

Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).

Breast Cancer Res Treat 2019 Mar 26. Epub 2019 Mar 26.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

Purpose: Inflammatory breast cancer (IBC) rates increased in the United States before the turn of the twenty-first century. We examine trends by estrogen receptor (ER) status since then.

Methods: Using data from the Surveillance, Epidemiology, and End Results (SEER) program for years 2001-2015, we calculated age-adjusted incidence rates for IBC (defined by AJCC TNM category T4d, extent of disease codes, and morphology code 8530) by ER status, which was imputed if unknown, among women aged 25-84 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05193-0DOI Listing
March 2019
1 Read

Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.

Breast Cancer Res Treat 2019 Mar 21. Epub 2019 Mar 21.

Department of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1192 East Newport Center Drive, Deerfield Beach, FL, 33442, USA.

Purpose: Metastatic breast cancer is regarded as an incurable entity. In heavily pretreated patients with increasingly limited options for palliative management, ensuring proper quality of life continues is to be an elusive issue. With this in mind, the authors evaluated the efficacy and safety of the Vinorelbine/Capecitabine doublet (VINOCAP). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05203-1
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05203-1DOI Listing
March 2019
7 Reads

Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.

Breast Cancer Res Treat 2019 Mar 21. Epub 2019 Mar 21.

Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany.

Purpose: In high-risk early breast cancer, adjuvant taxane-Gemcitabine combinations result in a recurrence-free survival similar to single-agent taxanes. However, haematologic toxicities and need for dose reductions are more frequent in combinations. Which option ultimately provides a better quality of life (QoL) is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05171-6DOI Listing

Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.

Breast Cancer Res Treat 2019 Mar 20. Epub 2019 Mar 20.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, People's Republic of China.

Purpose: BRCA1/2 germline mutations are associated with a high risk of breast cancer, which may preclude mutation carriers from breast-conserving surgery (BCS). This study retrospectively examined whether mutation status influenced the rate of ipsilateral breast tumor recurrence (IBTR) after BCS  in Chinese women.

Methods: Patients who underwent BCS were enrolled in carriers group and non-carriers group according to their BRCA1/2 mutation status in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05199-8DOI Listing
March 2019
1 Read

Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.

Breast Cancer Res Treat 2019 Mar 20. Epub 2019 Mar 20.

Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Purpose: Real-world data are critical to demonstrate the reproducibility of evidence and external generalizability of randomized clinical trials. Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6 that has been shown to improve progression-free survival (PFS) when combined with letrozole or fulvestrant in phase 3 clinical trials. We evaluated real-world outcomes in metastatic breast cancer patients who received palbociclib in combination with endocrine therapy in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05176-1DOI Listing
March 2019
3 Reads

Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.

Breast Cancer Res Treat 2019 Mar 20. Epub 2019 Mar 20.

Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 50, 90029, Oulu, Finland.

Purpose: To address the possible association between the use of metformin, other forms of antidiabetic medication (ADM) and statins with the incidence of breast cancer in women with type 2 diabetes (T2D).

Methods: Data were collected from a Finnish nationwide diabetes database (FinDM). The study cohort consisted of women diagnosed with T2D in 1996-2011 in Finland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05185-0DOI Listing
March 2019
1 Read

Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.

Breast Cancer Res Treat 2019 Mar 18. Epub 2019 Mar 18.

Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

Objective: To assess adherence to endocrine therapy and its relation to recurrence and mortality in women with early breast cancer.

Methods: This is a retrospective cohort study in population-based cancer registries in two Catalonian provinces of Spain. We included all cases of invasive stage I-III breast cancer diagnosed from 2007 to 2011 and with follow-up to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05201-3DOI Listing

Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.

Breast Cancer Res Treat 2019 Mar 16. Epub 2019 Mar 16.

Cancer Care Ontario, Toronto, Canada.

Purpose: Studies examining symptom differences between surgeries for breast cancer patients rarely incorporate the effects of adjuvant treatment choice. We sought to understand differences in patient-reported symptoms between lumpectomy plus radiation and mastectomy in the year following surgery.

Methods: This cohort study used linked administrative datasets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05196-xDOI Listing
March 2019
2 Reads

Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.

Breast Cancer Res Treat 2019 Mar 14. Epub 2019 Mar 14.

Department of Breast Surgery, Rigshospitalet/Herlev-Gentofte Hospital, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark.

Purpose: To determine the incidence and risk factors of sentinel lymph node (SN) and non-SN metastases in patients with microinvasive breast cancer (MIBC, T1). This to identify MIBC patients in whom axillary staging can be safely omitted.

Methods: The Danish Breast Cancer Group database was used to identify a total of 409 women with breast cancer ≤ 1 mm who underwent sentinel lymph node biopsy (SLNB) between 2002 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05200-4DOI Listing
March 2019
1 Read

Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.

Breast Cancer Res Treat 2019 Mar 13. Epub 2019 Mar 13.

Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.

Purpose: To evaluate the prognostic effect of the integration of genomic and transcriptomic profiles in breast cancer.

Methods: Eight hundred and ten samples from the Cancer Genome Atlas (TCGA) data sets were randomly divided into the training set (540 subjects) and validation set (270 subjects). We first selected single-nucleotide polymorphism (SNPs) and genes associated with breast cancer prognosis in the training set to construct the prognostic prediction model, and then replicated the prediction efficiency in the validation set. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05177-0DOI Listing
March 2019
2 Reads
3.940 Impact Factor

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.

Breast Cancer Res Treat 2019 Mar 13. Epub 2019 Mar 13.

Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.

Purpose: Quality of life (QoL) plays an important role in recovery-especially after an incisive diagnosis such as breast cancer. Here, we present a comprehensive assessment of QoL for pre- and postmenopausal patients, starting from initial systemic treatment of early breast cancer until 3 years later, in patients from a so-called "real-world" setting.

Methods: 251 premenopausal and 478 postmenopausal patients with early breast cancer have been recruited into the longitudinal MaLife project within the prospective, multicentre, German Tumour Registry Breast Cancer between 2011 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05197-wDOI Listing
March 2019
3 Reads

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.

Breast Cancer Res Treat 2019 Mar 13. Epub 2019 Mar 13.

Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

Purpose: Tumor-infiltrating lymphocytes (TILs) are associated with pathological complete response (pCR) and survival after neoadjuvant chemotherapy (NAC) in patients with early breast cancer. We investigated the prognostic and predictive role of TILs, macrophages, and HLA class 1 expression after NAC with or without the potentially immune modulating compound zoledronic acid (ZA).

Methods: Baseline tumor biopsies from 196 patients in the NEOZOTAC trial were analyzed for CD8 (cytotoxic T-cells), FoxP3 (regulatory T-cells), CD68 (macrophages), and HLA class I (HCA2/HC10) expression by immunohistochemistry and subsequently related to pCR and disease-free survival (DFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05195-yDOI Listing
March 2019
6 Reads

Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.

Breast Cancer Res Treat 2019 Mar 13. Epub 2019 Mar 13.

Comprehensive Cancer Center Erlangen-EMN, Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Nuremberg, Germany.

Purpose: Several clinical trials have investigated the prognostic and predictive usefulness of molecular markers. With limited predictive value, molecular markers have mainly been used to identify prognostic subgroups in which the indication for chemotherapy is doubtful and the prognosis is favorable enough for chemotherapy to be avoided. However, limited information is available about which groups of patients may benefit from additional therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05198-9DOI Listing
March 2019
6 Reads

Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.

Breast Cancer Res Treat 2019 Mar 11. Epub 2019 Mar 11.

Departments of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL, 33612, USA.

Purpose: Leptomeningeal disease is a rare presentation of advanced metastatic breast cancer. The purpose of this study was to evaluate craniospinal progression between intrathecal (IT) trastuzumab, IT chemotherapy, and whole brain radiation therapy (WBRT) in leptomeningeal disease.

Methods: A total of 56 patients were identified with breast cancer leptomeningeal disease at our institution treated with IT trastuzumab (n = 18; 32%), single-agent IT chemotherapy (methotrexate n = 14 or thiotepa n = 1; 27%), or WBRT alone (n = 23; 41%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05170-7DOI Listing
March 2019
1 Read

Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.

Breast Cancer Res Treat 2019 Mar 9. Epub 2019 Mar 9.

Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, 108 N. Greene Street, Baltimore, MD, 21201, USA.

Purpose: Triple-negative breast cancer (TNBC) has been ranked as one of the devastating malignancy worldwide. Its disease progression and treatment obstacle is associated with the negligible expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 (HER2). Due to a lack of growth hormone receptors, TNBC is desperately demanding effective therapeutic regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05183-2DOI Listing
March 2019
2 Reads

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.

Breast Cancer Res Treat 2019 Mar 9. Epub 2019 Mar 9.

Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 4000 Reservoir Road NW, 120 Building D, Washington, DC, 20057-1400, USA.

Purpose: HER2-targeted therapies have substantially improved the outcome of patients with breast cancer, however, they can be associated with cardiac toxicity. Guidelines recommend holding HER2-targeted therapies until resolution of cardiac dysfunction. SAFE-HEaRt is the first trial that prospectively tests whether these therapies can be safely administered without interruptions in patients with cardiac dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05191-2DOI Listing
March 2019
1 Read

Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network.

Breast Cancer Res Treat 2019 Mar 9. Epub 2019 Mar 9.

University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.

Purpose: Chronic upper extremity disability (UED) is common after breast cancer treatment but under-identified and under-treated. Although UED has been linked to quality of life (QoL), the role of UED as mediator between contemporary treatment practices and QoL has not been quantified. This investigation describes UED in a contemporary sample of breast cancer patients and examines its relationship with personal and treatment factors and QoL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05184-1DOI Listing
March 2019
4 Reads